Compare Neurocrine Biosciences Inc (NBIX) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nasdaq Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Nasdaq Inc trades at $94.7 (market cap $53.13B). The key difference: Nasdaq Inc is far larger — about 3.4× Neurocrine Biosciences Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NDAQ | |
|---|---|---|
Market Cap | $15.77B | $53.13B |
Sector | Health | Financials |
52-Week High | $185.50 | $100.98 |
52-Week Low | $123.10 | $76.85 |
Enterprise Value | $15.78B | $59.58B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Nasdaq (NDAQ) trades at $95.04, down 1.9% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, up from $7.4B in 2024, and net income margin improved to 22.52%. Recent news highlights Nasdaq's acquisition of Dasseti to enhance AI capabilities in investment technology.
The outlook for NDAQ is positive, supported by consistent earnings outperformance, revenue growth, and strategic acquisitions. Risks include market volatility and competitive pressures. Analysts maintain a bullish consensus with a $109.20 price target, implying 15% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
